Navigation Links
Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
Date:3/11/2009

-- Roche intends to acquire all outstanding shares of Genentech for US$95.00 per share in cash

-- Research and early development to operate as an independent center; South San Francisco site to become headquarters of combined U.S. commercial operations; Genentech's unique culture to be maintained

-- Innovation will be enhanced through a diversity of research approaches and sharing of IP, technologies, partnerships and other key assets

-- Transaction expected to be EPS accretive in the first year after closing

BASEL and SOUTH SAN FRANCISCO, March 12 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The special committee of Genentech's Board of Directors has approved the agreement and recommends that Genentech shareholders tender their shares in Roche's tender offer.

Dr. Charles Sanders, Chairman of the Special Committee of Genentech's Board of Directors, said: "We believe this is a fair offer for Genentech shareholders, and the Committee is pleased to come to a successful conclusion of this process. We look forward to working with Roche to complete the transaction as expeditiously as possible."

Franz B. Humer, Chairman of the Roche Group, said: "We are very pleased that we have reached an agreement with Genentech and secured a positive recommendation from the special committee. As stated previously, an agreed transaction offers clear and important advantages for the shareholders of both companies. I am delighted that the intensive negotiations have led to a successful c
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests
2. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
3. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
4. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
5. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
6. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
7. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
8. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
9. Roche completes acquisition of ARIUS
10. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
11. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Local veterinarian, ... Veterinary Hospital are seeking candidates to participate in an ... osteoarthritis. The ultimate goal of this study is ... cells into one or two arthritically affected joints can ... , Candidates for the current investigational study must ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... August 29, 2014 Due to a misstatement ... week, the Adult Stem Cell Technology Center, LLC ( ASCTC ... stem cell therapy research that might benefit ALS patients. ... for new stem cell technologies and therapeutic applications, FRC listed ... Bucket Challenge donors who wish not to support research ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... New Sequence Data into Biochips for Gene Expression Profiling ... , LEXINGTON, Mass. and HEIDELBERG, Germany, June 29 ... today the launch of the first biochip on the ... biochip from febit enables up-to-date profiling and enrichment of ...
... for ANX-530 NDA re-started , , SAN DIEGO, June ... ) today announced its plans for the remainder of 2009. ... earlier this month, ADVENTRX has re-started the final manufacturing activities ... Company will continue to evaluate the data from its recently-completed ...
... the Drug Information Association (DIA)-- , , NORTHBROOK, ... held biopharmaceutical company, today announced the appointment of Jeffrey ... and chief medical officer. , , Dr. Sherman ... Horizon and will lead the regulatory and clinical strategy ...
Cached Biology Technology:febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment 2febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment 3ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 2ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 3Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer 2
(Date:8/28/2014)... app called TX Invasives is now available from the ... Texas at Austin for identifying harmful non-native plant, insect ... in the United States cause about $137 billion in ... crops, clog waterways, kill native plants and more. , ... for reporting where invasive species occur, we,re more likely ...
(Date:8/28/2014)... America (ESA) is pleased to announce the selection of ... Society. Honorary Membership acknowledges those who have served ESA ... the affairs of the Society that has reached an ... the ESA Governing Board and then voted on by ... the Awards Ceremony at Entomology 2014, ESA,s Annual Meeting ...
(Date:8/28/2014)... researchers have identified a handful of bacterial culprits that ... disease and ulcerative colitis, using patients, own intestinal immune ... Aug. 28 in the journal Cell . , ... which plays a critical role in the development and ... small number of bacterial species affect a person,s susceptibility ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Yale study identifies possible bacterial drivers of IBD 2
...  GenesisSolutions (An ABS Group Company), a Fully Integrated Global ... Sciences EAM Symposium for Engineering, Maintenance & Reliability professionals ... in Cary, North Carolina . ... provide participants with examples of Asset Management Best Practices ...
... led by researchers at Children,s National Medical Center has ... for the treatment of Duchenne muscular dystrophy (DMD). The ... , show that the drug, VBP15, decreases inflammation and ... linked to current treatments with glucocorticoids such as prednisone. ...
... Practice is the title and the main message of ... Sept. 30-Oct. 2. Physicians from more than 40 states ... hear and learn about the latest developments and research ... into the medical practice. "Our goal is to ...
Cached Biology News:Life Sciences EAM Symposium 2Life Sciences EAM Symposium 3New muscular dystrophy treatment shows promise in early study led by Children's National 2Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference 2
Includes USB cable, custom driver and one roll of thermal paper...
Mycoplasma and virus tested...
... 10X BlueJuice Gel Loading ... easy loading and tracking ... agarose or native polyacrylamide ... features higher density sucrose ...
Ready-to-use solution....
Biology Products: